| Literature DB >> 35052788 |
Hui Li1, Wen Wen1, Jia Luo1,2.
Abstract
Pancreatitis and alcoholic pancreatitis are serious health concerns with an urgent need for effective treatment strategies. Alcohol is a known etiological factor for pancreatitis, including acute pancreatitis (AP) and chronic pancreatitis (CP). Excessive alcohol consumption induces many pathological stress responses; of particular note is endoplasmic reticulum (ER) stress and adaptive unfolded protein response (UPR). ER stress results from the accumulation of unfolded/misfolded protein in the ER and is implicated in the pathogenesis of alcoholic pancreatitis. Here, we summarize the possible mechanisms by which ER stress contributes to alcoholic pancreatitis. We also discuss potential approaches targeting ER stress and UPR in developing novel therapeutic strategies for the disease.Entities:
Keywords: FDA-approved drugs; alcohol abuse; cell signaling; oxidative stress; therapy
Year: 2022 PMID: 35052788 PMCID: PMC8773075 DOI: 10.3390/biomedicines10010108
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1Alcohol exposure and ER stress. Alcohol and its metabolites may cause ER stress and induce a cellular adaptive response known as the unfolded protein response (UPR) in the pancreas. UPR is controlled by three transmembrane sensor proteins: inositol-requiring enzyme 1α (IRE1α), protein kinase RNA-like ER kinase (PERK) and activating transcription factor 6 (ATF6). Under non-stressed conditions, these sensor proteins bind to GPR78 and possibly MANF in a calcium-dependent manner. Alcohol exposure results in the accumulation of unfolded or misfolded proteins in the ER, in turn causing the release of GRP78/MANF to activate UPR. The activation of UPR regulates transcriptional and translational programs by restoring protein folding, promoting protein degradation, or inducing cell death.
Figure 2Possible etiology of alcohol-related pancreatitis. (1) A pre-existing ER condition resulting from stressors other than alcohol (tobacco, high-fat diet, etc.) is further exacerbated by alcohol exposure, causing irreversible damage to the ER and subsequent cell death. (2) Genetic mutations in UPR or ERAD compromise the ability of the ER to deal with unfolded/misfolded proteins, and therefore sensitize the ER to alcohol-induced damages, leading to severe ER stress and pancreatic damages. (3) Pre-exposure to alcohol compromises the ability of the ER to maintain homeostasis and makes the ER susceptible to subsequent alcohol exposure or other ER stressors, resulting in severe pancreatic damages.
Figure 3Potential pharmacological intervention for alcoholic pancreatitis targeting ER homeostasis. It is of great potential to identify specific molecules or strategies targeting ER stress and different UPR components. One of the most direct pharmacological approaches to alleviate ER stress is to use chemical chaperones, such as 4-PBA and TUDCA, to facilitate protein folding and alleviate ER stress. Another effective approach is to use specific small-molecule inhibitors or activators to modulate different UPR components. Among the three arms of UPR, PERK/eIF2α is the most important in controlling the protein translation and the transition to apoptotic cell death and has therefore drawn greater attention. A number of small molecules targeting this pathway have been shown to have protective effects against ER-stress-induced damage. Recently, several FDA-approved drugs that can affect some UPR components exhibit potential benefits to alleviate ER stress and reduce pancreatic damages. One of the potential mechanisms for alcohol-induced ER stress is the perturbation of ER calcium homeostasis. Small molecules targeting calcium channels have therapeutic potential for ER-stress-induced pancreatic damage. Antioxidants, such as vitamin C and vitamin E have been shown to alleviate ER stress and may be useful to treat alcoholic pancreatitis. Gene therapy using recombinant viruses, such as adeno-associated viruses (AAVs) is becoming an attractive strategy to deliver active UPR components to specific tissues to mitigate ER stress. AAV delivery of several key UPR proteins, such as GRP78 and MANF, demonstrates promising benefits to treat ER-stress-related tissue damage.
Candidate small molecules targeting ER stress for the treatment of alcohol-related pancreatitis.
| Molecule | Experimental Model/Clinical Settings | Effects | Ref. |
|---|---|---|---|
| Chemical chaperones | |||
| Sodium phenylbutyrate (4-PBA) | CCK-stimulated rat pancreatic acini; taurocholate-induced AP rats | Rescue cell death; protect pancreas | [ |
| UDCA | Idiopathic AP and recurrent pancreatitis patients | Remove gallstones and prevent pancreatitis relapse | [ |
| Tauroursodeoxycholic acid (TUDCA) | CCK-8-stimulated rat pancreatic acini; caerulein-induced AP rats | Reduce cell death, trypsin activation and edema formation | [ |
| PERK/eIF2α inhibitors | |||
| Salubrinal | Caerulein/LPS-induced-AP mice | Reduce serum amylase level, inflammation and cell death | [ |
| Guanabenz acetate (GA) | Mouse model of neurological diseases | Exert neuroprotection | [ |
| Trazodone (TZD) | Small-molecule-screen for β-cell proliferation in transgenic zebrafish | Stimulate proliferation of pancreatic β cells | [ |
| Dibenzoylmethane (DBM) | Mouse models of dementia | Improve neuroprotection and cognition; no toxicity to pancreas | [ |
| IRE1α Inhibitors | |||
| STF-083010 | Alcohol-treated mouse pancreas 266-6 acinar cells | Reduce cell death | [ |
| Kinase-Inhibiting RNase-Attenuator 6 (KIRA6) | Akita diabetic mice | Reduce cells death of pancreatic islets in vitro and in vivo | [ |
| ATF6 inhibitors | |||
| Melatonin | LPS-treated rat AR42J acinar cells; | Attenuate inflammation, reduce apoptosis | [ |
| Bix | Gerbil model of forebrain ischemia; mouse model of renal I/R injury | Rescue cell death | [ |
| Compound 147 (AA 147) | Mouse model of acute myocardial infarction | Cytoprotective effects in heart, brain, kidney and liver | [ |
| Inhibitors of CRAC channels | |||
| GSK-7975A | AP mice induced by TLCA3S, caerulein or ethanol and palmitoleic acid | Reduce serum amylase level, cell death and inflammation | [ |
| CM_128/CM4620 | Phase I clinical trials for AP | [ |